Page 10 of 19 · 436 questions tagged vendor-vetting.
What I have: KP · dulaglutide. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am interested in a…
The case in front of me: 96.8% · liraglutide · QSC. I want to decide this in advance so that I am not deciding it under pressure later. Assume I will follow the plan…
I would rather spend on verification than on volume. I have done this once and I suspect I got away with it rather than got it right. For context: I keep records of…
Stated plainly: QSC · mazdutide. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources all citing each other.…
The case in front of me: TFC · Wuhan Wansheng Biotechnology. I would like the axes of comparison first and the recommendation second. I have tried the first option…
The method section is present, which is unusual enough that I want to make use of it. I would like help reading this properly rather than being told what conclusion…
For reference: QYB · Qingdao Saber Technology. I am trying to choose between two options that are usually discussed as though only one exists. I am not optimising for…
Setup, so nobody has to ask: WXT · Xi’an Mokemei Biotechnology. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I…
I have the report as a PDF with the chromatogram on page two, so I can quote specifics. I suspect the usual explanation for this is wrong, or at least incomplete. I…
This is my second independent submission on material from the same supplier. I would like to understand the steps well enough to explain them to someone else. I have…
What I have: 98.2% · dulaglutide · SSA. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can tell me which work…
The thing that stops me going ahead is not the price, it is that I would be sending money with no recourse whatsoever. With a card I have a dispute right; if nothing…
Setup, so nobody has to ask: 99.1% · mazdutide · TFC. I would like to set this up properly once, rather than adjust it repeatedly. My budget is real but not tight,…
The lot number on the vial matches the certificate, which at least rules out the easy problem. I have done this once and I suspect I got away with it rather than got…
The particulars: QYB · semaglutide. An unexpected observation, and I would like a differential rather than reassurance. The conditions were within what I understood…
This is my second independent submission on material from the same supplier. This is presented as though it settles something, and I am not convinced it does. I have…
The case in front of me: CPC · oral semaglutide. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries and…
What I have: cagrilintide · lot-specific certificate. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone…
Conditions: list of related substances · SSA. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
What I am working with: BCH · a GLP-1 receptor agonist. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources…
Numbers first: SWB · orforglipron. Before I write this off, I want to check whether it is a known failure mode. I have the lot number, the certificate and the date,…
For reference: GL Biochem · semaglutide. Somebody stated this to me confidently and I would like to check it before repeating it. I would accept a well-reasoned…
The specifics, since they change the answer: 96.8% · survodutide · WWB. I am at the decision point and I would rather think it through than improvise. I would rather…
Numbers first: SGN · orforglipron. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence exists and…